CN102369017A - 用于微创系统性递送包含TGF-β超家族成员的蛋白质的组合物和方法 - Google Patents

用于微创系统性递送包含TGF-β超家族成员的蛋白质的组合物和方法 Download PDF

Info

Publication number
CN102369017A
CN102369017A CN2010800147720A CN201080014772A CN102369017A CN 102369017 A CN102369017 A CN 102369017A CN 2010800147720 A CN2010800147720 A CN 2010800147720A CN 201080014772 A CN201080014772 A CN 201080014772A CN 102369017 A CN102369017 A CN 102369017A
Authority
CN
China
Prior art keywords
bmp
biological agent
site
disease
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800147720A
Other languages
English (en)
Chinese (zh)
Inventor
M·E·皮库特勾德
D·施瑞尔
A·R·皮尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of CN102369017A publication Critical patent/CN102369017A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
CN2010800147720A 2009-02-12 2010-02-12 用于微创系统性递送包含TGF-β超家族成员的蛋白质的组合物和方法 Pending CN102369017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15190209P 2009-02-12 2009-02-12
US61/151,902 2009-02-12
PCT/US2010/024124 WO2010093941A2 (en) 2009-02-12 2010-02-12 COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS

Publications (1)

Publication Number Publication Date
CN102369017A true CN102369017A (zh) 2012-03-07

Family

ID=42111852

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800147720A Pending CN102369017A (zh) 2009-02-12 2010-02-12 用于微创系统性递送包含TGF-β超家族成员的蛋白质的组合物和方法

Country Status (8)

Country Link
US (4) US20100204124A1 (enExample)
EP (1) EP2396026A2 (enExample)
JP (2) JP5819734B2 (enExample)
CN (1) CN102369017A (enExample)
AU (1) AU2010213591B2 (enExample)
CA (1) CA2752160A1 (enExample)
SG (1) SG173634A1 (enExample)
WO (1) WO2010093941A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137613A2 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US9158383B2 (en) 2012-03-02 2015-10-13 Microsoft Technology Licensing, Llc Force concentrator

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587063A (en) * 1982-07-15 1986-05-06 Kao Corporation Process for the preparation of phosphoric diesters
US20030022830A1 (en) * 1996-03-22 2003-01-30 Charette Marc F. Methods for enhancing functional recovery following central nervous system ischemia or trauma
US20040176292A1 (en) * 1998-01-23 2004-09-09 Charette Marc F. Methods and compositions for enhancing cognitive function using morphogenic proteins
US20050143304A1 (en) * 1996-05-06 2005-06-30 Curis, Inc. Novel therapies for chronic renal failure

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578063A (en) * 1984-09-14 1986-03-25 W. L. Gore & Assoc., Inc. Central venous catheter
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5674844A (en) 1991-03-11 1997-10-07 Creative Biomolecules, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US6506729B1 (en) 1991-03-11 2003-01-14 Curis, Inc. Methods and compositions for the treatment and prevention of Parkinson's disease
US6800603B2 (en) 1991-03-11 2004-10-05 Curis, Inc. Morphogen-induced neural cell adhesion
US6949505B1 (en) 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
CZ282231B6 (cs) * 1991-06-05 1997-06-11 The Procter And Gamble Company Prostředek na generování nového růstu kosti v savci
US5693615A (en) * 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
KR100259827B1 (ko) 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
CA2129820C (en) 1992-02-12 2003-06-17 Helge Neidhardt Dna sequences encoding novel growth/differentiation factors
WO1994010203A2 (en) 1992-11-03 1994-05-11 Creative Biomolecules, Inc. Op-3-induced morphogenesis
WO1994015966A1 (en) 1993-01-12 1994-07-21 Johns Hopkins University School Of Medicine Growth differentiation factor-9
EP0690871A4 (en) 1993-01-12 1999-10-20 Univ Johns Hopkins Med GROWTH DIFFERENTIATION FACTOR-5
CA2157577C (en) 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
US5447725A (en) 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
JPH09503903A (ja) 1993-07-09 1997-04-22 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−６
EP0725796A4 (en) 1993-10-08 1999-12-01 Univ Johns Hopkins Growth differentiation factor-10
JP3300500B2 (ja) 1993-10-12 2002-07-08 新日本製鐵株式会社 疲労強度、降伏強度および被削性に優れる熱間鍛造用鋼の製造方法
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
EP0733109B9 (en) 1993-12-07 2006-07-05 Genetics Institute, LLC Bmp-12, bmp-13 and tendon-inducing compositions thereof
IL114397A0 (en) 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
DE69534468T2 (de) 1994-07-08 2006-07-13 The Johns Hopkins University School Of Medicine Wachstums-differenzierungsfaktor-11
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US5635372A (en) 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
WO1999015191A2 (en) * 1997-09-19 1999-04-01 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Cytokines having neurotrophic activity
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
US6846906B1 (en) 1998-10-07 2005-01-25 Stryker Corporation Modified proteins of the TGF-β superfamily, including morphogenic proteins
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
US6677432B1 (en) 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
BR0209198A (pt) * 2001-04-26 2004-06-08 Control Delivery Sys Inc Métodos de sìntese de compostos contendo fenol
DK1677735T3 (da) * 2003-10-17 2014-10-27 Joslin Diabetes Center Inc Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
CA2561809A1 (en) 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
EP1750743A4 (en) * 2004-04-29 2009-07-08 Glaxosmithkline Zagreb ORAL PREPARATIONS CONTAINING BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF METABOLIC BONE DISEASES
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
CA2567405A1 (en) 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
AU2005251741B2 (en) * 2004-06-03 2009-09-24 Genera Istrazivanja D.O.O. Insulin-independent, bone morphogenetic protein (BMP)-mediated uptake of blood glucose by peripheral cells and tissues
US7901395B2 (en) * 2005-08-16 2011-03-08 Borden Jonathan R Catheter having staggered lumens and method
ATE543833T1 (de) 2005-12-22 2012-02-15 Janssen Biotech Inc Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
JP2011211450A (ja) 2010-03-30 2011-10-20 Victor Co Of Japan Ltd 立体映像表示装置、立体映像撮像装置および立体映像表示方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587063A (en) * 1982-07-15 1986-05-06 Kao Corporation Process for the preparation of phosphoric diesters
US20030022830A1 (en) * 1996-03-22 2003-01-30 Charette Marc F. Methods for enhancing functional recovery following central nervous system ischemia or trauma
US20050143304A1 (en) * 1996-05-06 2005-06-30 Curis, Inc. Novel therapies for chronic renal failure
US20040176292A1 (en) * 1998-01-23 2004-09-09 Charette Marc F. Methods and compositions for enhancing cognitive function using morphogenic proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAPLAN LD.: "A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-relate complex", <BIOTECHNOL THER》 *
LUKE S.G.E. HOWARD: "New therapeutic agents for pulmonary vascular disease", 《PAEDIATRIC RESPIRATORY REVIEWS》 *

Also Published As

Publication number Publication date
SG173634A1 (en) 2011-09-29
US20140187473A1 (en) 2014-07-03
US20140342976A1 (en) 2014-11-20
AU2010213591B2 (en) 2013-11-21
CA2752160A1 (en) 2010-08-19
EP2396026A2 (en) 2011-12-21
JP5819734B2 (ja) 2015-11-24
JP2014169337A (ja) 2014-09-18
US20100204124A1 (en) 2010-08-12
US20130316949A1 (en) 2013-11-28
JP2012517483A (ja) 2012-08-02
WO2010093941A3 (en) 2010-10-28
AU2010213591A1 (en) 2011-08-18
WO2010093941A2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CN102369016A (zh) 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
ES2447516T3 (es) Formulaciones de liberación sostenida que comprenden cristales BMP-7
JP5819734B2 (ja) ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法
AU2013206500A1 (en) Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
AU2013206499A1 (en) Peripheral administration of proteins including TGF-beta superfamily members for systemic treatment of disorders and disease
WO2000062796A1 (fr) Agents de traitement des troubles de la fonction pancreatique
Migliore Intranasal delivery of GDNF for the treatment of Parkinson's disease
JPH06116166A (ja) 脳血管攣縮予防または治療剤
EP4429693A1 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
HK1097460B (en) Process for producing injectable gabapentin compositions
HK1097460A1 (en) Process for producing injectable gabapentin compositions
JPWO2000062796A1 (ja) 膵臓機能障害改善剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120307